Drug Metabolism as a Community Effort

R. Hitchings, Libusha Kelly

Research output: Contribution to journalShort survey

Abstract

Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

Original languageEnglish (US)
Pages (from-to)235-237
Number of pages3
JournalCell metabolism
Volume30
Issue number2
DOIs
StatePublished - Aug 6 2019

Fingerprint

Levodopa
Pharmaceutical Preparations
Bacteria
Parkinson Disease
Enzymes

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology

Cite this

Drug Metabolism as a Community Effort. / Hitchings, R.; Kelly, Libusha.

In: Cell metabolism, Vol. 30, No. 2, 06.08.2019, p. 235-237.

Research output: Contribution to journalShort survey

Hitchings, R. ; Kelly, Libusha. / Drug Metabolism as a Community Effort. In: Cell metabolism. 2019 ; Vol. 30, No. 2. pp. 235-237.
@article{8e259a9db36947fcae7b813dde6f7629,
title = "Drug Metabolism as a Community Effort",
abstract = "Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.",
author = "R. Hitchings and Libusha Kelly",
year = "2019",
month = "8",
day = "6",
doi = "10.1016/j.cmet.2019.07.005",
language = "English (US)",
volume = "30",
pages = "235--237",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Drug Metabolism as a Community Effort

AU - Hitchings, R.

AU - Kelly, Libusha

PY - 2019/8/6

Y1 - 2019/8/6

N2 - Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

AB - Levodopa (L-dopa) is the primary treatment for Parkinson's disease. The gut microbiome can metabolize levodopa, potentially leading to decreased efficacy and side effects, but responsible bacteria were unknown. Maini Rekdal et al. (2019) characterize enzymes in two gut bacteria that sequentially metabolize L-dopa and identify a novel inhibitor that may improve outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85069941586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069941586&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2019.07.005

DO - 10.1016/j.cmet.2019.07.005

M3 - Short survey

VL - 30

SP - 235

EP - 237

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 2

ER -